Barrett JS - Search Results

1

PhRMA perspective on population and individual bioequivalence.

Barrett JS, Batra V, Chow A, Cook J, Gould AL, Heller AH, Lo MW, Patterson SD, Smith BP, Stritar JA, Vega JM, Zariffa N. Barrett JS, et al. J Clin Pharmacol. 2000 Jun;40(6):561-70. doi: 10.1002/j.1552-4604.2000.tb05980.x. J Clin Pharmacol. 2000. PMID: 10868305 Review.

2

Update to the PhRMA perspective on population and individual bioequivalence.

Barrett JS, Batra V, Chow A, Cook J, Gould AL, Heller AH, Lo MW, Patterson SD, Smith BP, Stritar JA, Vega JM, Zariffa N. Barrett JS, et al. J Clin Pharmacol. 2000 Jun;40(6):571-2. doi: 10.1002/j.1552-4604.2000.tb05981.x. J Clin Pharmacol. 2000. PMID: 10868306 No abstract available.

3

Moricizine bioavailability via simultaneous, dual, stable isotope administration: bioequivalence implications.

Pieniaszek HJ Jr, Mayersohn M, Adams MP, Reinhart RJ, Barrett JS. Pieniaszek HJ Jr, et al. Among authors: barrett js. J Clin Pharmacol. 1999 Aug;39(8):817-25. doi: 10.1177/00912709922008489. J Clin Pharmacol. 1999. PMID: 10434234 Clinical Trial.

4

Leveraging Big Data in Pediatric Development Programs: Proceedings From the 2016 American College of Clinical Pharmacology Annual Meeting Symposium.

Mulugeta LY, Yao L, Mould D, Jacobs B, Florian J, Smith B, Sinha V, Barrett JS. Mulugeta LY, et al. Among authors: barrett js. Clin Pharmacol Ther. 2018 Jul;104(1):81-87. doi: 10.1002/cpt.975. Epub 2018 Jan 10. Clin Pharmacol Ther. 2018. PMID: 29319159

5

Population pharmacokinetic meta-analysis with efavirenz.

Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ Jr. Barrett JS, et al. Int J Clin Pharmacol Ther. 2002 Nov;40(11):507-19. doi: 10.5414/cpp40507. Int J Clin Pharmacol Ther. 2002. PMID: 12698988

6

Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers.

Fossler MJ, Ebling WF, Ma S, Kornhauser D, Mondick J, Barrett JS, Garner D, Quon CY, Pieniaszek HJ Jr. Fossler MJ, et al. Among authors: barrett js. J Clin Pharmacol. 2002 Dec;42(12):1326-34. doi: 10.1177/0091270002042012003. J Clin Pharmacol. 2002. PMID: 12463727 Clinical Trial.

7

The effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240.

Cirillo I, Martin NE, Brennan B, Barrett JS. Cirillo I, et al. Among authors: barrett js. J Clin Pharmacol. 2004 Dec;44(12):1379-84. doi: 10.1177/0091270004269557. J Clin Pharmacol. 2004. PMID: 15545308 Clinical Trial.

8

Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis.

Barrett JS, Gibiansky E, Hull RD, Planès A, Pentikis H, Hainer JW, Hua TA, Gastonguay M. Barrett JS, et al. Int J Clin Pharmacol Ther. 2001 Oct;39(10):431-46. Int J Clin Pharmacol Ther. 2001. PMID: 11680668 Clinical Trial.

9

Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.

Pfister M, Martin NE, Haskell LP, Barrett JS. Pfister M, et al. Among authors: barrett js. J Clin Pharmacol. 2004 Jun;44(6):621-31. doi: 10.1177/0091270004265365. J Clin Pharmacol. 2004. PMID: 15145970 Clinical Trial.

10

Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.

Barrett JS, Hainer JW, Kornhauser DM, Gaskill JL, Hua TA, Sprogel P, Johansen K, van Lier JJ, Knebel W, Pieniaszek HJ Jr. Barrett JS, et al. Thromb Res. 2001 Feb 15;101(4):243-54. doi: 10.1016/s0049-3848(00)00412-6. Thromb Res. 2001. PMID: 11248285 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

230 results

Search Page